Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 7/20 | 0.42 |
| ▸ | TLR2 | O60603 | 9/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13416457 | 0.86 | MEN1 (0.44) | MEN1KMT2ACA2TLR2DPP7 | |
| SCHEMBL14135506 | 0.85 | MEN1 (0.42) | MEN1KMT2ACA2TLR2SMN1; SMN2 | |
| SCHEMBL13416236 | 0.83 | DPP7 (0.42) | TLR2DPP7 | |
| SCHEMBL14135433 | 0.81 | GNAI3 (0.51) | MEN1KMT2ACA2TLR2DPP7 | |
| SCHEMBL13416268 | 0.81 | RRM1 (0.42) | TLR2DPP7 | |
| SCHEMBL13416086 | 0.80 | CTSC (0.43) | MEN1KMT2ACA2TLR2DPP7 | |
| SCHEMBL13416283 | 0.79 | MEN1 (0.54) | MEN1KMT2ACA2TLR2SMN1; SMN2 | |
| SCHEMBL13416746 | 0.78 | DPP7 (0.40) | MEN1KMT2ACA2TLR2DPP7 | |
| SCHEMBL13416245 | 0.77 | ALDH1A1 (0.31) | — | |
| SCHEMBL14135391 | 0.76 | GLP1R (0.40) | MEN1KMT2ATLR2DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2010-04-22 | — | — | US | disclosed |
| WO-2008095841-A2 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | MEN1 615/4885KMT2A 4459/4885CA2 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.